Dividend yield of Retrophin, Inc.
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|BOH Bank of Hawaii Corporation||NYSE > Finance > Major Banks||2.93|
|BLD TopBuild Corp.||NYSE > Basic Industries > Engineering & Construction||2.93|
|BREW Craft Brew Alliance, Inc.||NASDAQ > Consumer Non-Durables > Beverages (Production/Distribution)||2.93|
|CSSE Chicken Soup for the Soul Entertainment, Inc.||NASDAQ > Consumer Services > Movies/Entertainment||2.93|
|FNV Franco-Nevada Corporation||NYSE > Basic Industries > Precious Metals||2.93|
|ACXM Acxiom Corporation||NASDAQ > Technology > EDP Services||2.93|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||2.93|
|BRACU Black Ridge Acquisition Corp.||NASDAQ > Finance > Business Services||1,482.86|
|VNCE Vince Holding Corp.||NYSE > Consumer Services > Clothing/Shoe/Accessory Stores||1,676.00|
|ANTH Anthera Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||1,690.00|
|W Wayfair Inc.||NYSE > Consumer Services > Catalog/Specialty Distribution||2,786.29|
|HYAC Haymaker Acquisition Corp.||NASDAQ||3,183.33|
|CMSS CM Seven Star Acquisition Corporation||NASDAQ > Finance > Business Services||4,865.00|